Research on genomic test utilizing next generation sequencer for solid tumors and development of the genome database

Research on genomic test utilizing next generation sequencer for solid tumors and development of the genome database - Genomic test for solid tumors and genome database

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028388

Enrollment

9000

Registered

2017-08-01

Start date

2017-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors (Brain tumor, Thyroid cancer, Parathyroid cancer, Breast cancer, Lung adenocarcinoma, Lung squamous cell carcinoma, Tongue cancer, Carcinoma of the oral cavity, Pharyngeal cancer, Esophageal cancer, Gastric cancer, Carcinoma of the small intestine, Colon cancer, Rectal cancer, Gastrointestinal stromal tumor, Hepatocellular carcinoma, Intrahepatic bile duct cancer, Extrahepatic bile duct cancer, Gallbladder cancer, Ampullary cancer, Pancreatic cancer, Duodenal cancer, Rena

Interventions

Genomic test CANCERPLEX-JP OncoGuide NCC oncopanel system FndationONe CDx genome profile GUARDANT360 MSI Analysis System BRACAnalysis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who underwent biopsy and/or surgical resection for the solid tumors (Brain tumor, Thyroid cancer, Parathyroid cancer, Breast cancer, Lung adenocarcinoma, Lung squamous cell carcinoma, Tongue cancer, Carcinoma of the oral cavity, Pharyngeal cancer, Esophageal cancer, Gastric cancer, Carcinoma of the small intestine, Colon cancer, Rectal cancer, Gastrointestinal stromal tumor,Hepatocellular carcinoma, Intrahepatic bile duct cancer, Extrahepatic bile duct cancer, Gallbladder cancer, Ampullary cancer, Pancreatic cancer, Duodenal cancer, Renal cell carcinoma, Urothelial carcinoma, Bladder cancer, Prostate cancer, Carcinoma of the cervix uteri, Carcinoma of the corpus uteri, Ovarian cancer, Skin cancer) 2. Primary tumor and/or treatment lesions are pathologically revealed as the above mentioned solid tumors 3. History of the anti-cancer drug treatments is not considered 4. Patients with written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Development of genome database	—

Secondary

Measure	Time frame
Development of genome analytic technologies Association between genomic alterations and the sensitivity of anti-cancer drugs Development of artificial intelligence to predict genomic aberrations and the response of anti-cancer drugs in patients with solid tumors	—

Countries

Japan

Contacts

Public ContactToshifumi Wakai

Niigata University Graduate School of Medical and Dental Sciences Division of Digestive and General Surgery

wakait@med.niigata-u.ac.jp025-227-2228

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026